Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Status:
Active, not recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Phase 2

Dana-Farber Cancer Institute

Pharmacyclics LLC.